Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
367-05-014 ISMRM Abstract

The impact of metformin on brain CBF and hypoxia in the EAE model of multiple sclerosis: Quantified R2* and CBF at 9.4T

Primary: Neuro - Multiple Sclerosis
Secondary: Preclinical Animal & in vitro MR - Biomarkers
367-05-014 · Neuroinflammation: Myelin and Iron · Monday, 11 May, 4:10 PM–5:05 PM · Digital Posters Row H
Keywords: Treatment Response Multiple Sclerosis Perfusion MRI Hypoxia 9.4T MRI
Accepted
Abbey Palset1,2,3, Ying Wu1,2,3, Mahir Rahman1,2,3, Demitra M Selimos1,2,3, Mada Hashem1,2,3, Ty Makarowski1,2,3, Maryam Mobarakabadi2,3, Wee Yong2,3, Jeff F Dunn 1,2,3
1Department of Radiology, University of Calgary, Calgary, Canada
2Hotchkiss Brain Institute, University of Calgary, Calgary, Canada
3Cumming School of Medicine, University of Calgary, Calgary, Canada
Presenting Author: Jeff F Dunn

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Geurts JJ, Barkhof F. Grey matter pathology in multiple sclerosis. The Lancet Neurology. 2008;7(9):841-851.
2. Yang R, Dunn JF. Reduced cortical microvascular oxygenation in multiple sclerosis: a blinded, case-controlled study using a novel quantitative near-infrared spectroscopy method. Scientific reports. 2015;5(1):16477.
3. Chandler HL, Stickland RC, Patitucci E, et al. Reduced brain oxygen metabolism in patients with multiple sclerosis: Evidence from dual-calibrated functional MRI. Journal of Cerebral Blood Flow & Metabolism. 2023;43(1):115-128.
4. Johnson TW, Wu Y, Nathoo N, Rogers JA, Wee Yong V, Dunn JF. Gray matter hypoxia in the brain of the experimental autoimmune encephalomyelitis model of multiple sclerosis. PLoS One. 2016;11(12):e0167196.
5. Du Y, Zhu Y-J, Zhou Y-X, Ding J, Liu J-Y. Metformin in therapeutic applications in human diseases: Its mechanism of action and clinical study. Molecular Biomedicine. 2022;3(1):41.
6. Jiang T, Yu JT, Zhu XC, et al. Acute metformin preconditioning confers neuroprotection against focal cerebral ischaemia by pre‐activation of AMPK‐dependent autophagy. British journal of pharmacology. 2014;171(13):3146-3157.
7. Negrotto L, Farez MF, Correale J. Immunologic effects of metformin and pioglitazone treatment on metabolic syndrome and multiple sclerosis. JAMA neurology. 2016;73(5):520-528.
8. Buxton RB. Quantifying CBF with arterial spin labeling. Journal of magnetic resonance imaging : JMRI. Dec 2005;22(6):723-6. doi:10.1002/jmri.20462 [doi]
9. Brooks D, Leenders K, Head G, Marshall J, Legg N, Jones T. Studies on regional cerebral oxygen utilisation and cognitive function in multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry. 1984;47(11):1182-1191.

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/367-05-014